IFN-α2 inhibitors constitute a distinct class of chemical compounds characterized by their ability to selectively target and modulate the activity of interferon-alpha 2 (IFN-α2), a type of cytokine integral to the intricate network of immune system regulation. These inhibitors are designed to interact with specific molecular components involved in the IFN-α2 signaling cascade, thereby exerting regulatory influence over the cellular responses triggered by this cytokine. Structurally, IFN-α2 inhibitors can encompass a variety of chemical scaffolds and functional groups, enabling them to bind to key protein targets, receptors, or downstream elements within the IFN-α2 pathway. Through these interactions, IFN-α2 inhibitors interfere with the transmission of intracellular signals that initiate and sustain the immune response.
By selectively attenuating IFN-α2-related signaling events, these compounds offer the potential to modulate immune cell activities and molecular processes linked to immune function, without affecting other cytokine signaling pathways. As research progresses, a deeper understanding of the chemical mechanisms underpinning IFN-α2 inhibitors may unlock novel avenues for manipulating immune responses and elucidate broader implications for the field of immune system regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Although primarily known as a Janus kinase (JAK) inhibitor, ruxolitinib can indirectly influence the activity of IFN-α2 by affecting JAK-STAT signaling pathways involved in cytokine signaling. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
Similar to ruxolitinib, baricitinib is a JAK inhibitor with potential effects on interferon signaling pathways. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
While primarily used for malaria and certain autoimmune conditions like lupus and rheumatoid arthritis, hydroxychloroquine has been explored for its potential to inhibit interferon-alpha production. | ||||||
Apremilast | 608141-41-9 | sc-480062 | 5 mg | $444.00 | ||
Apremilast is a phosphodiesterase 4 (PDE4) inhibitor that could potentially modulate immune responses and cytokine production, including interferon-alpha. | ||||||
Filgotinib | 1206161-97-8 | sc-507393 | 10 mg | $150.00 | ||
Filgotinib is a JAK1 inhibitor that could impact interferon-alpha signaling as part of its broader effects on cytokine pathways. | ||||||